Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature

PHASE3CompletedINTERVENTIONAL
Enrollment

247

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Type 1 Diabetes
Interventions
DEVICE

Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature

Automatic suspension of insulin delivery when glucose is low.

DEVICE

Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump

No Automatic suspension of insulin delivery when glucose is low.

Trial Locations (17)

10032

Naomie Barrie Diabetes Center, New York

13210

Joslin Diabetes Center, Syracuse

30046

Physicians Research Associates, Lawrenceville

Endocrine Research Solutions, Roswell

30309

Atlanta Diabetes Associates, Atlanta

33401

Metabolic Research Institute, West Palm Beach

45701

Ohio University College of Osteopathic Medicine, Athens

50314

Iowa Diabetes and Endocrinology Research Center, Des Moines

53717

University of Wisconsin - Madison, Madison

55416

International Diabetes Center, Minneapolis

72205

Arkansas Diabetes Clinic and Research Center, Little Rock

78731

Texas Diabetes, Austin

80045

University of Colorado Denver/ Barbara Davis Center for Childhood Diabetes, Aurora

83404

Rocky Mountains Diabetes and Osteoporosis Center, Idaho Falls

92026

AMCR Institute, Inc, Escondido

94401

Frank Diabetes Research Institute/ Mills-Peninsula Health Center, San Mateo

98057

Rainier Clinical Research Center, Renton

All Listed Sponsors
lead

Medtronic Diabetes

INDUSTRY

NCT01497938 - Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature | Biotech Hunter | Biotech Hunter